Brief: Nanobiotix Announces Achievement Of $20M Development Milestone Payment Related To Ongoing Global Phase 3 Head And Neck Cancer Study
29/01/2024 21:17
Jan 29 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES ACHIEVEMENT OF $20M DEVELOPMENT
MILESTONE
PAYMENT RELATED TO ONGOING GLOBAL PHASE 3 HEAD AND NECK CANCER
STUDY
* NANOBIOTIX SA - $20M REPRESENTS FIRST APPLICABLE
DEVELOPMENT
MILESTONE FROM GLOBAL LICENSING AGREEMENT EXECUTED BETWEEN
NANOBIOTIX AND JANSSEN
Source text for Eikon: ID:nGNEfJDb0
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering